ApexOnco Front Page Recent articles 17 March 2025 Astra gives in vivo Car-T its biggest endorsement The company buys Belgium’s EsoBiotec for $425m. 17 March 2025 Otsuka bids for a seat at the conjugate table The acquisition of Araris follows a 2023 discovery collaboration. 7 October 2024 Ipsen casts doubt on Pfizer’s prostate plan Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer. 4 October 2024 Roche expands in KRAS GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF. 4 October 2024 J&J ramps up its bladder cancer battle The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda. 2 October 2024 BeiGene tries where others failed The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants. 2 October 2024 The month ahead: October’s upcoming events Approval decisions loom for Opdivo and Lumakras, and earnings season starts again. 2 October 2024 AbbVie has Met phase 3, again The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development. Load More Recent Quick take The first-quarter curtain falls on Pieris and Gamida 28 March 2024 Novocure’s brain mets win comes with caveats 28 March 2024 Syndax menin inhibitor gets its big day 27 March 2024 After zolbetuximab investors look for a Claudin18.2 encore 26 March 2024 Another false dawn for Nkarta 22 March 2024 NextCure doubles down on Lair 22 March 2024 Again, Keytruda and PARP fail to lynk 21 March 2024 Innate gets a new lacutamab blow 21 March 2024 BioNTech has some cancer convincing to do 20 March 2024 New Breyanzi approval comes at a timely moment for Allogene 18 March 2024 Load More Most Popular